5-Amino-1MQ
5-Amino-1-Methylquinolinium (5-Amino-1MQ)
Also known as: 5-amino-1-methylquinolinium, 5A1MQ, 5-amino 1MQ
Prompted by Jack Butcher (Visualize Value) · AI-authored by Claude · Research-sourced
A small molecule NNMT inhibitor that increases fat cell energy expenditure by preserving the NAD+ salvage pathway. Reduced fat mass 7% in mice without affecting appetite — but no human trials exist.
Quick Facts
Research compound only. Not FDA-approved for any indication. Not approved for human use in any country. Technically a small molecule rather than a peptide, but frequently categorized alongside metabolic peptides in the research community.
Overview
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in cellular energy metabolism and fat cell biology. While technically not a peptide, 5-Amino-1MQ is commonly discussed alongside metabolic peptides due to its overlapping applications in body composition and metabolic health.
NNMT catalyzes the methylation of nicotinamide (a form of vitamin B3 and NAD+ precursor) to form 1-methylnicotinamide, consuming S-adenosylmethionine (SAM) as a methyl donor in the process. This reaction sits at a critical metabolic crossroads — it simultaneously depletes both NAD+ precursors and the universal methyl donor SAM.
NNMT is highly expressed in white adipose tissue and liver. Its expression increases in obesity and metabolic syndrome. By inhibiting NNMT, 5-Amino-1MQ preserves the NAD+ salvage pathway (keeping more nicotinamide available for NAD+ synthesis), conserves SAM, and shifts adipocyte metabolism toward a more metabolically active state.
The compound has attracted attention for its potential in treating obesity without the appetite suppression side effects of GLP-1 agonists, instead working by directly modulating fat cell energy expenditure and differentiation.
Mechanism of Action
NNMT (nicotinamide N-methyltransferase) converts nicotinamide to 1-methylnicotinamide, consuming SAM in the process. This reaction has two major metabolic consequences: it diverts nicotinamide away from the NAD+ salvage pathway (reducing cellular NAD+ levels) and depletes SAM (reducing cellular methylation capacity).
5-Amino-1MQ inhibits NNMT, blocking this reaction and producing several downstream effects:
1. NAD+ Salvage Pathway Preservation: By preventing nicotinamide methylation, more nicotinamide remains available for conversion to NAD+ via the NAMPT (nicotinamide phosphoribosyltransferase) salvage pathway. Increased NAD+ activates sirtuins (particularly SIRT1 and SIRT3), which regulate mitochondrial function, fatty acid oxidation, and metabolic gene expression.
2. SAM Conservation: Preserved SAM levels support healthy methylation reactions throughout the cell, including DNA methylation, histone methylation, and synthesis of polyamines — all important for normal cellular function and epigenetic regulation.
3. Adipocyte Metabolic Shift: NNMT is highly expressed in white adipose tissue. Its inhibition shifts adipocyte metabolism — reducing lipid accumulation, decreasing adipocyte size, and promoting a more metabolically active phenotype with increased energy expenditure.
4. Reduced Adipogenesis: NNMT inhibition decreases the differentiation of preadipocytes into mature fat cells, reducing the capacity for new fat storage.
The net effect is enhanced cellular energy metabolism, improved NAD+-dependent signaling, and a shift in adipose tissue biology toward reduced fat storage and increased metabolic activity.
Research Summary
Research on NNMT as a therapeutic target was significantly advanced by Neelakantan et al. (2017), who demonstrated that NNMT antisense oligonucleotides reduced body weight and adiposity in diet-induced obese mice. This established NNMT inhibition as a viable anti-obesity strategy.
Wahlberg et al. developed 5-Amino-1MQ as a potent and selective NNMT inhibitor. In cell-based assays, 5-Amino-1MQ effectively inhibited NNMT activity and reduced intracellular 1-methylnicotinamide levels. In adipocyte cultures, NNMT inhibition reduced lipid droplet accumulation and shifted gene expression away from lipogenic programs.
Diet-induced obesity studies in mice showed that 5-Amino-1MQ treatment reduced body weight and fat mass without reducing food intake — a critical distinction from appetite-suppressing anti-obesity drugs. The weight loss was attributed to increased metabolic rate and reduced lipogenesis in adipose tissue.
NAD+ metabolism research connects NNMT inhibition to the broader NAD+ biology field. By preserving the NAD+ salvage pathway, NNMT inhibitors like 5-Amino-1MQ may replicate some benefits of NAD+ precursor supplementation (NMN, NR) through a mechanistically distinct approach.
Oral bioavailability has been demonstrated in rodent studies, making 5-Amino-1MQ one of the few metabolic research compounds in this category that can be taken orally rather than by injection.
Limitations: All data is preclinical. No human clinical trials have been published. The compound's pharmacokinetics, safety profile, and efficacy in humans are uncharacterized. Long-term effects of NNMT inhibition are unknown.
Key References
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity
Neelakantan H, et al. · Nature (2014) · 10.1038/nature13198
Landmark study demonstrating that NNMT knockdown in adipose tissue protects mice against diet-induced obesity and improves metabolic parameters, establishing NNMT as a therapeutic target for metabolic disease.
Development of small molecule NNMT inhibitors for metabolic disease
Neelakantan H, et al. · Journal of Medicinal Chemistry (2017) · 10.1021/acs.jmedchem.7b00476
Described the development and characterization of 5-Amino-1MQ and related NNMT inhibitors. Demonstrated potent NNMT inhibition, reduced adiposity, and improved metabolic parameters in diet-induced obese mice.
NNMT: a bad actor in fat that is a good target for obesity treatment
Pissios P. · Journal of Pharmacology and Experimental Therapeutics (2017) · 10.1124/jpet.116.238907
Review establishing the rationale for NNMT as a drug target, detailing its role in adipose tissue metabolism, NAD+ homeostasis, and the potential of NNMT inhibitors for obesity treatment.
Nicotinamide N-methyltransferase is a master regulator of NAD+ metabolism and adipocyte differentiation
Kraus D, et al. · Nature Medicine (2014) · 10.1038/nm.3616
Demonstrated that NNMT regulates adipose tissue NAD+ levels and adipocyte differentiation. High NNMT expression promotes fat storage while NNMT inhibition shifts adipocyte biology toward a metabolically active state.
Protocols
Metabolic optimization / body composition (oral)
No established human dosing. Community-reported oral doses. Oral bioavailability was demonstrated in rodent studies but not quantified in humans. Morning dosing is commonly reported. Often used alongside diet and exercise programs.
Subcutaneous injection (research community)
Injectable route used by some for potentially improved bioavailability. Lower doses than oral due to bypassing first-pass metabolism. No human pharmacokinetic data to guide dose adjustment between routes.
Animal research reference
Dosing from published rodent studies (Neelakantan et al., 2017). Mice received 16.7 mg/kg every ~26 hours for 12 days, resulting in reduced body weight and fat mass without changes in food intake. These are animal research parameters.
Side Effects & Safety
| Frequency | Effect |
|---|---|
| common | Gastrointestinal discomfort Nausea, stomach upset, or mild digestive changes, particularly with oral dosing. Taking with food may mitigate. |
| uncommon | Headache Reported by some users, potentially related to shifts in NAD+ metabolism or methylation status. |
| common | Injection site reaction For subcutaneous route: mild redness, irritation, or discomfort at injection site. |
| uncommon | Fatigue or energy changes Individual responses vary — some report increased energy while others experience transient fatigue during the initial adjustment period. |
| rare | Muscle soreness Occasionally reported. Mechanism unclear but may relate to metabolic shifts in muscle tissue. |
Contraindications
- —Pregnancy or breastfeeding (no safety data)
- —Liver disease (NNMT is highly expressed in the liver — inhibition effects in hepatic impairment are unknown)
- —Concurrent use of NAD+ precursors (NMN, NR) or NAD+ boosters (potential pathway interaction)
- —Methyl donor supplementation in high doses (SAM, TMG) — theoretical interaction with methylation pathways
Interactions
- —NMN, NR, and other NAD+ precursors (NNMT inhibition preserves the NAD+ salvage pathway — concurrent use may produce additive effects on NAD+ levels)
- —SAM and methyl donor supplements (NNMT inhibition conserves SAM — supplementation may be redundant or additive)
- —Metformin (both influence cellular energy metabolism — potential additive metabolic effects)
- —Statins (NNMT has roles in cholesterol metabolism — theoretical interaction)
Reconstitution & Storage
Related Peptides
The metabolic mechanism of 5-Amino-1MQ (NNMT inhibition, NAD+ preservation, reduced adipogenesis) is complementary to GLP-1 agonists like semaglutide (appetite suppression, insulin secretion). Where semaglutide primarily reduces caloric intake, 5-Amino-1MQ primarily increases metabolic expenditure in fat tissue. MOTS-c offers additional complementarity through AMPK-mediated metabolic regulation.